

# Call for Patients with Friedreich's Ataxia Phase III Trial with SNT/MC17/idebenone

January 3, 2008

Dear FARA Patient Registry Participant:

We are pleased to be able to announce today that Santhera Pharmaceuticals is now recruiting patients with Friedreich's Ataxia in the United States, for a Phase III clinical research trial looking at the effects of idebenone on the nervous system and the heart.

***We are looking for patients between the ages of 8 and 17 years who have been diagnosed with Friedreich's Ataxia.***

**To participate, you must be able to:**

- Walk at least 33 feet without accompanying person
- Not have participated in the Phase II idebenone study sponsored by the NIH

**About the study**

- Participation in the study is for 9 months; 6 of those months you will be treated with study medication or placebo (an inactive pill with no drug in it)
- There are 3 possible treatments: 2 different doses of idebenone or a placebo
- There are 5 visits to the hospital
  - Travel costs are fully paid for, including hotel

---

*\* Santhera Pharmaceuticals additionally offers all patients that successfully complete the study the opportunity to participate in a follow-on study. In this study all patients will receive high-dose idebenone for up to one year free of charge.*

---

The purpose of the study is to show idebenone's clinical benefit on the nervous system and the heart in patients with Friedreich's Ataxia.

For more information about this study and to find out how to take part, please contact one of the following:

**Lisa Friedman, BS / Children's Hospital of Philadelphia, PA / Tel.: (267) 426 – 7538**  
Email: [friedmanl@email.chop.edu](mailto:friedmanl@email.chop.edu)

**Susan Perlman, MD / University of California Los Angeles, CA / Tel.: (310) 794 - 1225**  
Email: [SPerlman@mednet.ucla.edu](mailto:SPerlman@mednet.ucla.edu)

**Jennifer Farmer from FARA / Email: [Jen.Farmer@curefa.org](mailto:Jen.Farmer@curefa.org)**

In participating in clinical studies, you and other study participants make an important contribution to advancing the treatment of Friedreich's Ataxia.

Thank you for your ongoing support of FARA and clinical research in Friedreich's Ataxia.